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Summary
Both adaptive designs and group sequential designs are effective in reducing the
number of treatment failures in a clinical trial. Adaptive designs accomplish this
goal by randomizing, on average, a higher proportion of patients to the more suc-
cessful treatment. Group sequential designs, on the other hand, accomplish this
through early stopping. So we can find the better treatment early and thus more
patients can be allocated to the better treatments. Both designs satisfy a compro-
mise between individual and collective ethics and hence are attractive to clinician.
In this thesis, for fixed sample size, we compare the expected number of treatment
failures for three designs – the randomized play-the-winner rule, Pocock test and
O’Brien-Fleming test. The first design is an example of an adaptive design while
the last two are examples of group sequential designs. Simulation results show that
group sequential tests are generally more effective at reducing the expected number
of treatment failures than the RPW rule. And finally we show that the expected
number of treatment failures can be further reduced if the group sequential designs
viii




1.1 Ethical Concerns in Clinical Trials
In traditional experimental designs of clinical trials, the number of patients re-
cruited and the probabilities with which patients are allocated to treatments are
fixed in advance, e. g. , if there are two treatments A and B, the patients are assigned
to treatment A or B with equal probability of 0.5. However, in clinical trails there
is often an ethical requirement to minimize the number of patients recruited. Also,
in a trial comparing two alternative treatments, the number of patients receiving
the less promising treatment should be kept as small as possible.
The following example addressed the ethical concerns in clinical trials. Connor
et al. (1994) reported a clinical trial to evaluate the hypothesis that the antiviral
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therapy AZT reduces the risk of maternal-to-infant HIV transmission. A stan-
dard randomization scheme was used to obtain equal allocation to both AZT and
placebo, resulting in 239 pregnant women receiving AZT and 238 receiving placebo.
The endpoint was whether the newborn infant was HIV-negative or HIV-positive.
An HIV-positive newborn could be diagnosed within 12 weeks; a newborn could
be safely claimed to be HIV-negative within 24 weeks. At the end of the trials,
60 newborns were HIV-positive in the placebo group, while only 20 newborns were
HIV-positive in the AZT group. Three times as many infants in placebo group
have infected with HIV as infant in AZT group. Had they been given AZT, one
could say that many more infants might have been saved.
For decades, some leading biostatisticians, motivated by ethical considerations,
have explored alternatives to the typical design outlined above. Of them, adaptive
designs and group sequential designs are the two mostly used methods .
1.2 Adaptive Design
Different from traditional clinical trails which allocate patients to treatments with
equal probabilities, in adaptive designs, allocation is skewed in favor of treatments
with better performance thus far in the trial. For example, if there are two treat-
ments A and B, and if treatment A appears more successful than treatment B
during the clinical trial, then a new patient has greater chance of being allocated
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to treatment A than to treatment B. Thus in the trial as a whole, the numbers
of patients receiving different treatments may vary considerably. The use of an
adaptive design satisfies the ethical requirements mentioned in first section by at-
tempting to reduce the number of patients receiving inferior treatments.
Let’s take the AZT trial for example. A simulation study conducted by Yao
and Wei (1996) showed that, if the randomized play-the-winner Rule (one model
of adaptive designs) was used, about 57 of the infants would be HIV-positive (com-
pared with 80 infants in the previous trial.) Therefore, the ethical concern of clinical
trials have prompted research into adaptive designs in the past a few decades, with
the goal to allocate more patients to the better treatments in a clinical trial.
From the ethical point of view, it is ideal to allocate patients to better treatment
as many as possible. However,the ethics of clinical trials not only need to benefit
the health of patients, but to derive information about the effectiveness of the
treatments as well. In adaptive design, the allocation rules of patients in the
clinical trials are primary concerns. Urn models have been one of the most widely
used methods to solve this dilemma. The implementation of urn models will be
discussed in details in Chapter 2.
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1.3 Group Sequential Design
The use of a sequential designs satisfies the ethical requirement that the sample size
should be minimized. Clinical trials are usually, by their very nature, sequential ex-
periments, with patients entering and being randomized to treatment sequentially.
Monitoring the data sequentially as they accrue can allow early stopping if there is
sufficient evidence to declare one of the treatments superior, or if safety problems
arise. The theory of sequential analysis enables sequential monitoring of the data,
while still maintaining the integrity of the trial by preserving the specified error
rates.
Sequential medical trials have received substantial attention in the statistical lit-
erature. Armitage (1954) and Bross (1952) pioneered the use of sequential methods
in the medical field, particularly for comparative clinical trials, using fully sequen-
tial method. It was not until the 1970’s have the sequential methods gained rapid
development. Elfring and Schultz (1973) introduced the term “group sequential
design” and described their procedure for comparing two treatments with binary
response. McPherson (1974) suggested that the repeated significance test might
be used to analyze clinical trials data at a small number of interim analysis. How-
ever, the major impetus for group sequential methods came from Pocock (1977),
who gave clear guidelines for the implementation of group sequential experimental
designs attaining Type I error and power requirements. Pocock also demonstrated
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the versatility of the approach, showing that the nominal significance levels of re-
peated significance tests for normal response can be used reliably for a variety of
other responses and situations. Lan et al. (1982) suggested a method of stochastic
curtailment that allows unplanned interim analyses. In Lan’s method, early stop-
ping is based on calculating the conditional power, that is, the chance that the
results at the end of the trial will be significant, given the current data. Other
stochastic curtailment methods such as predictive power approach (Herson, 1979;
Spiegelhalter, 1986) and conditional probability ratio approach (Jennison, 1992;
Xiong, 1995) are also proposed. Hughes (1993) and Siegmund (1993) studied se-
quential monitoring of multiarm trials. Leung et al. (2003) consider a three-arm
randomized study which allows early stopping for both null hypothesis and alter-
native hypothesis.
The key feature of a group sequential test, as opposed to a fully sequential test,
is that the accumulating data are analyzed at intervals rather than after each new
observation. Such trials usually last for several months, even years and consume
substantial financial and patient resource, so continuous data monitoring can be a
serious practical burden The introduction of group sequential test has led to much
wider use of sequential methods. Their impact has been particularly evident in
clinical trials, where it is standard practice for a monitoring committee to meet at
regular intervals to assess various aspects of a study’s progress and it is relatively
easy to add formal interim analysis of the primary patient response. Not only are
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group sequential tests convenient to conduct, they also provide ample opportunity
for early stopping and can achieve most of the benefit of fully sequential tests in
terms of lower expected sample size and shorter average study lengths.
1.4 Organization of the Thesis
Two adaptive allocation rule PWR and RPW are introduced in Chapter 2. The
properties of a general family of adaptive designs, the Generalized Poˆlya Urn (GPU)
Model, are also presented. In Chapter 3, we discuss canonical joint distribution,
a unified form of group sequential designs. And critical values of two commonly
used methods, Pocock test and O’Brien-Fleming test (O’Brien and Fleming, 1979),
are given. The performance of adaptive designs and group sequential designs is
compared in Chapter 4. For given sample size, we compare the number of treatment




2.1 Randomized Play-the-winner Rule
The very first allocation rule in adaptive designs is the famous play-the-winner
rule (PWR) which was proposed by Zelen (1969). From then on, allocation rules
of adaptive designs in clinical trials have been extensively explored in theory. In
Zelen’s formulation, we assume that:
1. There are two treatments denoted by zero and one;
2. Patients enter the trial one at a time sequentially and are assigned to one of
the two treatments;
3. The outcome of a trial is a success or failure and only depends on the treat-
ment given.
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The rule for assigning a treatment to a patient is termed the “play-the-winner
rule” and is as follow: A success on a particular treatment generates a future trial on
the same treatment with a new patient. A failure on a treatment generates a future
trial on the alternate treatment. When there exists delayed response, that is to say,
the results of the treatment can not be obtained until the next patient enters the
trial, allocation is determined by tossing a fair coin. In PWR, the allocation scheme
is deterministic, and hence carried with it the biases of non-randomized studies.
Meanwhile, it do not take the case of the delayed responses into consideration.
But in the context of Zelen’s paper, we have perhaps the first mention that an urn
model could be used for the sequential design of clinical trials.
In 1978, Wei and Durham (1978) extended play-the-winner rule of Zelen (1969)
into the randomized play-the-winner rule (RPW). In RPW model, an urn contains
balls representing two treatments (say, A and B) and suppose that there are u
balls of each type in the urn initially. The outcomes of treatments are dichotomous
with two possible values: success or failure. When a patient enters the trial, a ball
is randomly drawn from the urn and replaced, and the appropriate treatment is
assigned. If the response of the patient is a success, an additional β balls of the same
type are added to the urn and an additional α balls of the opposite type are added
to the urn. If the response is a failure, then an additional β balls of the opposite
type are added to the urn and additional α balls of the same type are added into
the urn, where β ≥ α ≥ 0. We denote the above model by RPW(u, α, β).
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RPW rule keeps the spirit of the PWR rule in that it assigns more patients
to the better treatment. Moreover, this rule has its advantages that it is not
deterministic, less vulnerable to experimental bias and easily implemented in real
trial, and it allows delayed response by the patients. Wei and Durham (1978) also
proposed an inverse stopping rule which will stop the trial within a finite number
of stages.
2.2 Generalized Poˆlya Urn (GPU) Model
One large family of randomized adaptive designs can be developed from the gener-
alized Poˆlya urn (GPU) model (Athreya and Ney, 1972), which is originally desig-
nated by Athreya and Karlin (1968) as generalized Friedman’s urn (GFU) model.
The GPU model can be formulated as following: suppose an urn contains K
types of balls initially, which represent K types of treatments in the clinical trials.
Let Yi = (Yi1, Yi2, · · · , YiK) be the numbers of K types of balls after the ith drawing
in the urn, where Yik denotes the number of the kth type of balls. Yi is called the
urn composition at the ith step. Y0 = (Y01, Y02, · · · , Y0K) denotes the initial urn
composition. At stage i, a ball is drawn from the urn, say of type k, (k = 1, · · · , K)
and then the ith patient will be assigned to treatment k and the ball is replaced
to the urn . After we observe the outcome of the kth treatment, Rkl balls of type
l, for l = 1, · · · , K will be added to the urn. In the most general sense, Rkl can
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be random and can be some function of a random process outside the urn process.
This is what makes the model so appropriate for adaptive design (in our case, Rkl
will be a random function of patient response). A ball must always be generated
at each stage (in addition to the replacement), and so P{Rkl = 0, for all , k =
1, · · · , K, l = 1, · · · , K} is assumed to be 0.
We define R and E as K × K matrices: R = 〈〈Rkl, k, l = 1, · · · , K〉〉 and
E = 〈〈E(Rkl), k, l = 1, · · · , k〉〉. We refer to R as the rule and E as the generating
matrix.
Let λ1 be the largest eigenvalue of E, v = (v1, · · · , vK) be the left eigenvector
corresponding to λ1, normalized so that v · 1 = 1. For the generalized Poˆlya urn









where Nk(n) means the number of patients allocated to the kth treatment (k =
1, · · · , K) after n steps. Let λ2 denote the eigenvalue of the second largest real





′ → N(0, σ2) (2.3)
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where σ2 is a constant and Yn = (Yn1, Yn2, · · · , YnK) is the urn composition after n
steps.
It is easy to note that RPW(u, α, β) is a special case of generalized Poˆlya urn
with K = 2. Let pi be the probability of success on treatment i = 1, 2 (denote A
and B respectively) and qi = 1− pi. The distribution of Rij is given by
Rij = βδij + α(1− δij) with probability pi
αδij + β(1− δij) with probability qi
where i = 1, 2, j = 1, 2 and δij is the Kronecker delta. Then from the definition of
the generating matrices, we have
E =
βp1 + αq1 αp1 + βq1
αp2 + βq2 βp2 + αq2
 (2.4)
here E is a constant matrix and the maximal eigenvalue is simply the row sum:
λ1 = α + β. By simple calculation we can get the normalized left eigenvector v
and by (2.2) we could show that:
N1(n)
n
a.s.−−→v1 = αp2 + βq2
α(p1 + p2) + β(q1 + q2)
(2.5)




a.s.−−→v1 = αp2 + βq2
α(p1 + p2) + β(q1 + q2)
(2.6)
the ultimate urn composition of type A balls. In (2.5), if treatment A is better, the
number of patients assigned to treatment A will be larger than that to treatment
B, which is what we expect from the adaptive designs.
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2.3 Generalization of GPU Model
Several principal generalizations have been made in recent years to Athreya’s orig-
inal formulation of the randomized urn. The first great work should be attributed
to Smythe (1996). He defined an extended Poˆlya urn (EPU) model, under which
the expectation of the number of balls added at each step is restricted to be a
constant:
Eij ≥ 0 for j 6= i and
K∑
j=1
Eij = c ≥ 0 (2.7)
but the type i ball drawn does not have to be replaced, and in fact, additional type
i balls can be removed from the urn, subject to (2.7) and a restriction that one
cannot remove more balls of a certain type than are present in the urn so that E
is tenable .
The second generalization to the GPUmodel is the introduction of non-homogeneous
generating matrix, En, where the expected number of balls added to the urn change
across draws. En is the generating matrices for the nth draw. This model is studied
by Bai and Hu (1999). They derived the asymptotics for the GFU model with the
non-homogeneous generating matrices. They assume that there exists a strictly
positive matrices E, such that:
∞∑
n=1
n−1‖En − E‖∞ <∞ (2.8)
where E has a Jordan form decomposition. Then two main convergence results
(2.1) and (2.2) still hold. And furthermore they proved the asymptotic normality
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properties of the urn composition.
The third generalization involves a random generating matrix. This occurs
when the number of balls added at a draw is a function of the previous draws, in
some sense. Bai et al. (2002) investigated a new adaptive design and showed the
usual properties. In their design, a success of treatment i (i = 1, · · · , K) results in
the addition of a type i ball. A failure of treatment i results in balls being added
to the other K − 1 treatments, proportionally to their previous success rates. The
usual properties hold in this case.
Thus from the above history of adaptive designs, we can see that the urn models
have been playing a significant role when it comes to allocate new patients from
known previous responses. And fortunately the asymptotic properties of general





Firstly we will consider the basic two-sided test for comparing two treatments when
observations are normally distributed with common, known variance. We restrict
our attention to the testing for a difference in the mean response of two treatments.
Let XAi and XBi, i = 1, 2, · · · , denote the response of subjects allocated to two
treatments A andB respectively. Suppose responses of subjects receiving treatment
A are normally distributed with variance σ2 and mean µA, which we write
XAi ∼ N(µA, σ2), i = 1, 2, · · ·
Likewise, suppose
XBi ∼ N(µB, σ2), i = 1, 2, · · ·
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and all observations are independent.
Consider the problem of testing the null hypothesis of no treatment difference
H0 : µA = µB against H1 : µA 6= µB
with Type I error probability α. A maximum number of group, K, and a group
size, m, are chosen. Subjects are allocated to treatments according to a constrained
randomization scheme which ensures m subjects receive each treatment in every
group and the accumulating data are analyzed after each group of 2m responses.
For each k = 1, 2, · · · , K, a standardized statistic Zk is computed from the first
k groups of observations, and the test terminates with rejection ofH0 if |Zk| exceeds
a critical value ck. If the test continues to the Kth analysis and |ZK | < cK , it stops
at that point and H0 is accepted. The sequence of critical values, {c1, · · · , ck}, is
chosen to achieve a specified Type I error, and different types of group sequential
test give rise to different sequences (Jennison and Turnbull, 2000). The group size,
m, is determined separately by a power prespecified.
It is widely recognized that the use of standard single-stage, fixed-sample-size
test at each look would lead to an overall Type I error significantly higher than the
nominal level. For example, Armitage et al. (1969) reported that the probability
under H0 that |Zk| exceeds Φ−1(0.975) = 1.96 for at least one k, k = 1, · · · , 5
is 0.142, nearly three times the 0.05 significance level applied at each individual
analysis. Thus a number of methods have been proposed to determine proper
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critical values for maintaining a prespecified overall significance level in sequential
testing, to construct repeated confidence intervals with a given overall coverage
probability, and to obtain a valid confidence interval following a sequential trial.
3.2 Group Sequential Tests
The two best-known forms of group sequential tests are due to Pocock (1977) and
O’Brien and Fleming (1979). For the testing problem of Section 3.1, Pocock’s test












, k = 1, · · · , K. (3.1)
Pocock’s test adopted the idea of a repeated significance test at a constant signifi-
cance level, that is, c1 = · · · = cK .
Formally, the Pocock test can be written as
After stage k = 1, · · · , K − 1
if |Zk| ≥ cK stop, reject H0
otherwise continue to stage k + 1
after stage K
if |Zk| ≥ cK stop, reject H0
otherwise stop, accept H0
(3.2)
The constants cK are displayed in Table 3.1 for α=0.01, 0.05 and 0.1. They
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CK
K α=0.01 α=0.05 α=0.10
1 2.576 1.960 1.645
2 2.772 2.178 1.875
3 2.873 2.289 1.992
4 2.939 2.361 2.067
5 2.986 2.413 2.122
6 3.023 2.453 2.164
7 3.053 2.485 2.197
8 3.078 2.512 2.225
9 3.099 2.535 2.249
10 3.117 2.555 2.270
11 3.133 2.572 2.288
12 3.147 2.588 2.304
15 3.182 2.626 2.344
20 3.225 2.672 2.392
Table 3.1: Pocock tests: Ck for two-sided tests with K groups of observations and
Type I error probability α
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CK
K α=0.01 α=0.05 α=0.10
1 2.576 1.960 1.645
2 2.580 1.977 1.678
3 2.595 2.004 1.710
4 2.609 2.024 1.733
5 2.621 2.040 1.751
6 2.631 2.053 1.765
7 2.640 2.063 1.776
8 2.648 2.072 1.786
9 2.654 2.080 1.794
10 2.660 2.087 1.801
11 2.665 2.092 1.807
12 2.670 2.098 1.813
15 2.681 2.110 1.826
20 2.695 2.126 1.842
Table 3.2: O’Brien & Fleming tests: Ck for two-sided tests with K groups of
observations and Type I error probability α
are computed numerically using the joint distribution of the sequence of statistics
Z1, · · · , Zk. Details of this computation can be found in Chapter 19 of Jennison
and Turnbull (2000).
As an alternative to Pocock’s test with constant nominal significance levels,
O’Brien and Fleming (1979) chose ck = (K/k)
1/2cK (k = 1, · · · , K). So in O’Brien-
Fleming’s test the nominal significance levels needed to reject H0 at each analysis
increase as the study progresses.
The O’Brien & Fleming test can be written as:
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Figure 3.1: O’Brien-Fleming, Pocock and Haybittle-Peto stopping boundaries.
After stage k = 1, · · · , K − 1
if |Zk| ≥ cK
√
K/k stop, reject H0
otherwise continue to stage k + 1
after stage K
if |Zk| ≥ cK stop, reject H0
otherwise stop, accept H0
(3.3)
Values of CK which ensure an overall Type I error probability α are provided
in Table 3.2.
19
The Pocock test has narrower boundaries initially, affording a greater oppor-
tunity for very early stopping, whereas the O’Brien-Fleming test has the narrower
boundaries at later analyses and a smaller maximum sample size. Clearly, the
O’Brien-Fleming procedure spends much less Type I error in early stages than the
Pocock procedure.
Another form of group sequential test due to Haybittle (1971) and Peto et al.
(1976). Haybittle-Peto test uses a constant critical value (usually 3) up to the final
analysis, with the boundary at the final analysis adjusted to control the overall
Type I error at the desired level.
Figure 3.1 illustrates the differences in boundary shape of O’Brien-Fleming,
Pocock and Haybittle-Peto tests. The figure shows critical values for standardized
statistics Zk in tests with 10 groups of observations and Type I error rate α = 0.05.
3.3 Unified Distribution Theory
3.3.1 Canonical Joint Distribution
Now we will introduce a unified distribution theory that considers more general
situations. Suppose we would like to conduct two-armed comparison of treatment
and control in which treatment effect, θ, could be:
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• difference of two normal means
• difference of two binomial probabilities
• ratio of two binomial probabilities
• log hazard ratio
• log odds ratio
• any general coefficient in a regression model
And we intend to monitor the data a maximum of K times, say at calender time
τ1, τ2 · · · , τK . Define Ik = information at calendar time τk. At interim monitoring






where θˆk is an efficient estimator for θ using all the data available to us up to
analysis k, and se(θˆk) is the estimated standard error of θˆk. Information Ik here
means Fisher information and for all practical purposes it is well approximated by
Ik = [se(θˆk)]
−2. Then the asymptotic joint distribution of the sequence of Wald
statistics {Z1, Z2, · · · , ZK}, has the following properties regardless of the underlying
model generating the data:
(i) (Z1, · · · , ZK) is multivariate normal
(ii) Zk ∼ N(θ
√
Ik, 1) , k = 1, · · · , K
(iii) Cov(Zk1 , Zk2) =
√
Ik1/Ik2 , 1 ≤ k1 ≤ k2 ≤ K
(3.5)
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We say that those statistics with above properties have the canonical joint distribu-
tion with information levels {I1, · · · , IK} for the parameter θ. This general result
is due to Jennison and Turnbull (1997) and Scharfstein et al. (1997)
3.3.2 The Case of Equal Group Sizes
Let us consider a special case where test statistics is computed after equal incre-
ments of information, i.e., I1 = I, I2 = 2I, · · · , IK = KI, where I is some fixed
amount of information. For problems where response is instantaneous, whether this
response be discrete or continuous, the information is proportional to the number
of individuals so far in the study. In such a case, calculating the test statistic after
equal increments of information is equivalent to calculating the test statistic after
equal number of patients enrolled into the study.
Suppose it is required to test a null hypothesis H0 : θ = 0 with two-sided Type
I error probability α and power 1− β at θ = δ. When a fixed sample test is based
on Wald statistic, then we have
Z ∼ N(0, 1), under null hypothesis
and
Z ∼ N(δI1/2f , 1), under alternative hypothesis
If is the information required in fixed sample size design. Therefore, in order to
22




−1(1− α/2) + Φ−1(1− β),
or equivalently, we need to obtain the following information in order to get the
desired power
If = {Φ−1(1− α/2) + Φ−1(1− β)}/δ2 (3.6)
When the group sequential test with equal group size is used, the maximum infor-
mation level needed depends on K, α, β and the type of group sequential boundary
being used. We denote the maximum information level by Imax. We can specify the
the ratio of the maximum information of a group sequential test to the information
of a fixed sample size design. This ratio is called inflation factor (IF). Therefore
we have:
Imax = IF × If (3.7)
The inflation factor is a function of K, α, β and has been tabulated for some of
these parameters in Table 3.3 and Table 3.4. Again, details of their derivation can
be found in Chapter 19 of Jennison and Turnbull (2000).
We see from this table that the inflation factors are greater than one, which
means that the maximum information required using a group sequential test is
greater than the information required by a fixed sample size design to detect the
same treatment difference with the same power and significance level. But this does
not mean that a group sequential test is bad. Since a group sequential test allows
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IF
1− β=0.8 1− β=0.9
K α=0.01 α=0.05 α=0.10 α=0.01 α=0.05 α=0.10
1 1.000 1.000 1.000 1.000 1.000 1.000
2 1.092 1.110 1.121 1.084 1.100 1.110
3 1.137 1.166 1.184 1.125 1.151 1.166
4 1.166 1.202 1.224 1.152 1.183 1.202
5 1.187 1.229 1.254 1.170 1.207 1.228
6 1.203 1.249 1.277 1.185 1.225 1.249
7 1.216 1.265 1.296 1.197 1.239 1.266
8 1.226 1.279 1.311 1.206 1.252 1.280
9 1.236 1.291 1.325 1.215 1.262 1.292
10 1.243 1.301 1.337 1.222 1.271 1.302
11 1.250 1.310 1.348 1.228 1.279 1.312
12 1.257 1.318 1.357 1.234 1.287 1.320
15 1.272 1.338 1.381 1.248 1.305 1.341
20 1.291 1.363 1.411 1.264 1.327 1.367
Table 3.3: Pocock tests: Inflation factor IF to determine group sizes of two-sided
tests with K groups of observations and Type I error probability α and power 1-β
us to terminate a clinical trial early, so the average information (hence average
sample size) will be less than that of a fixed sample size design.
Since we have equally spaced information levels, we can get the information
level after the kth interim analysis:




{Φ−1(1− α/2) + Φ−1(1− β)}2
δ2
(3.8)
where k = 1, · · · , K.
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IF
1− β=0.8 1− β=0.9
K α=0.01 α=0.05 α=0.10 α=0.01 α=0.05 α=0.10
1 1.000 1.000 1.000 1.000 1.000 1.000
2 1.001 1.008 1.016 1.001 1.007 1.014
3 1.007 1.017 1.027 1.006 1.016 1.025
4 1.011 1.024 1.035 1.010 1.022 1.032
5 1.015 1.028 1.040 1.014 1.026 1.037
6 1.017 1.032 1.044 1.016 1.030 1.041
7 1.019 1.035 1.047 1.018 1.032 1.044
8 1.021 1.037 1.049 1.020 1.034 1.046
9 1.022 1.038 1.051 1.021 1.036 1.048
10 1.024 1.040 1.053 1.022 1.037 1.049
11 1.025 1.041 1.054 1.023 1.039 1.051
12 1.026 1.042 1.055 1.024 1.040 1.052
15 1.028 1.045 1.058 1.026 1.042 1.054
20 1.030 1.047 1.061 1.029 1.045 1.057
Table 3.4: O’Brien & Fleming tests: Inflation factor IF to determine group sizes of
two-sided tests with K groups of observations and Type I error probability α and
power 1-β
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Under H0 : θ = 0, the standardized statistics {Z1, · · · , ZK} have the null joint
distribution:
(i) (Z1, · · · , Zk) is multivariate normal
(ii) Zk ∼ N(0, 1) , k = 1, · · · , K
(iii) Cov(Zk1 , Zk2) =
√
k1/k2 , 1 ≤ k1 ≤ k2 ≤ K
(3.9)
The following distribution arises under alternative hypothesis when θ = ±δ:
(i) (Z1, · · · , Zk) is multivariate normal
(ii) Zk ∼ N(±{Φ−1(1− α/2) + Φ−1(1− β)}
√
k ∗ IF/K, 1) , k = 1, · · · , K
(iii) Cov(Zk1 , Zk2) =
√
k1/k2 , 1 ≤ k1 ≤ k2 ≤ K
(3.10)
Let {c1, c2, · · · , cK} be a sequence of numbers and we conduct the experiment
according the following procedure:
After group k = 1, · · · , K − 1
if |Zk| ≥ ck stop, reject H0
otherwise continue to group k + 1
after group K
if |Zk| ≥ ck stop, reject H0
otherwise stop, accept H0
(3.11)








P0 is the probability evaluated under the null hypothesis. Many ck’s satisfy the
above condition. Pocock’s test and O’Brien-Fleming test are two of them.
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(|Zj| < cj for j = 1, · · · , k − 1 and |Zk| ≥ ck)
}
(3.13)
P1 is the probability evaluated under the alternative hypothesis.
The general method of group sequential design can be summarized in the fol-
lowing five steps:
1. Identify the statistical model for the data to be observed and parameter θ
which is to have value zero under the null hypothesis. Specify δ, α and β.
The test of H0 : θ = 0 will have Type I error probability α and power 1− β
at θ = ±δ.
2. Choose the type of test, Pocock, O’Brien-Fleming, etc., and the maximum
number of analyses, K.
3. Define the standardized test statistics Zk, and find an expression for the
information levels Ik in terms of the numbers and the types of observations
available at each analysis, k = 1, · · · , K.
4. Find the inflation factor (IF) for the chosen test and number of analyses, K.
Calculate the information levels required at each analysis, Ik = (k/K)∗IF∗If ,
k = 1, · · · , K. Design the experiment so that these levels will be attained.
5. Run the experiment applying the stopping rule (3.11)
27
Chapter 4
Comparison of Two Designs
4.1 Test Statistics
In Chapter 2 and Chapter 3, I introduced the adaptive designs and group sequen-
tial designs respectively. Most proposed adaptive designs consider a fixed sample
size, and modify allocation probabilities during the course of the trial by some
mechanism to reflect the current trend of the data. In this way, the patient has
a higher chance of being allocated to the better treatment, or at least, to the one
performing better thus far in the trial. Group sequential designs inspect the data at
each interim monitor time and tend to use balanced randomization, but terminate
at the earliest point of convicting evidence.
Both adaptive designs and group sequential designs can reduce the number
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of treatment failures. Adaptive designs accomplish this goal by randomizing, on
average, a higher proportion to the more successful treatment. Group sequential
designs, on the other hand, accomplish this by declaring the better treatment
as early as possible. Both designs satisfy a compromise between individual and
collective ethics and hence are attractive to clinicians.
I will compare two designs for the problem of testing the difference between
the probabilities of success in two treatment arms of a clinical trial with binary
outcomes. And we assume that the patients’ responses are immediately obtainable.
Specifically, with fixed sample size, I compare the randomized play-the-winner rule
(RPW), an adaptive design, with Pocock test and O’Brien-Fleming test, two group
sequential designs.
Firstly, I will propose the test statistics used in the design of experiments.
Denoting the probabilities of success for patients receiving treatment A and B by
pA and pB, respectively (with qA = 1 − pA, qB = 1 − pB), and the difference by
θ = pA − pB, the usual hypothesis test is H0 : θ = 0 versus H1 : θ 6= 0. For
the RPW design, suppose that nA and nB patients receive treatment A and B,
respectively, with nA+nB = n, and that SA and SB are, respectively, the observed
number of successes on treatment A and B. The statistic used for RPW design in
the comparison is the standardized difference:
Z =
θˆ
{pˆA(1− pˆA)/nA + pˆB(1− pˆB)/nB}1/2 (4.1)
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where θˆ = pˆA − pˆB, pˆA = SA/nA, and pˆB = SB/nB. The Z statistic is asymptotic
normal under RPW rule. We will prove the asymptotic normality of Z in Section
4.2.
For the group sequential design, I suppose that the maximum number of groups
is K and in each group m patients are allocated to each treatment. Let SAk and
SBk denote the number of successes of treatment A and B respectively up to the
kth interim analysis. The statistic in the kth analysis (1 ≤ k ≤ K) is given by:
Zk =
θˆk
{pˆAk(1− pˆAk)/(mk) + pˆBk(1− pˆBk)/(mk)}1/2 (4.2)
where θˆk = pˆAk− pˆBk, pˆAk = SAk/(mk) and pˆBk = SBk/(mk). As shown in Chapter
3, the sequence {Z1, Z2, · · · , ZK} follows the canonical joint distribution (3.5).
4.2 Asymptotic Properties of Z Statistics
Firstly, I will provide a general result. Let θ be a vector-valued parameter from
a stochastic process of dimension s. Let the likelihood of the sample be Ln =














where L0 = 1. Let Fn be the sigma algebra generated by the stochastic process
through stage n, and define the conditional expectation of • with respect to Fn to
be En(•) and the conditional variance to be V arn(•). We will suppose there exists
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an open subset ω of the parameter space Ω containing the true parameter point
θ0.
We impose the following regularity conditions on the likelihood:
(A1)
∫
Pn(x1, · · · , xn;θ)dxn can be partially differentiated twice (with respect
to θ) under the integral sign and the first partials have finite moments of order
2 + δ (for some δ > 0).
(A2) For almost all x1, · · · , xn, Ln(θ) admits all third partial derivatives, and
the absolute values of the third partials (with respect to θj, θk, and θl) are bounded
by a functionMn(x1, · · · , xn) for all θ ∈ ω. We assumeMjkl = supnMn(X1, · · · , Xn)
is integrable.




a.s.−−→γjk(θ), as n→∞, where γjk(θ) is a nonrandom function of θ, for all θ ∈ ω.
(A4) For some δ > 0, n−(1+δ/2)
∑n
i=1
Ei−1{(∂/∂θj)Li(θ)}2+δ a.s.−−→0, j = 1, · · · , s,
as n→∞, for all θ ∈ ω.




P−→0, j = 1, · · · , s, as n→∞, for
all θ ∈ ω.





n→∞, for all θ ∈ ω, where γjk(θ) is defined in (A3).
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Define Γ(θ) be an s× s matrix with elements γjk(θ), where the are defined in
condition (A3). Let θn = (θˆ1n, · · · , θˆsn) be a MLE for θ. We have the following
theorem.
Theorem 1 (Rosenberger et al., 1997) If conditions (A1)–(A6) are satisfied,
then a consistent MLE, θˆ n, exists and the vector given by n
1/2(θˆjn − θj), for
j = 1, · · · , s, is asymptotically multivariate normal with mean zero and variance-
covariance matrix [Γ(θ)]−1, provided the inverse exists.
Proof: Let Ln(θ) ≡ logLn(θ) =
n∑
i=1
Ui(θ) be the log-likelihood, Suppose θ0 is
the true parameter,using Taylor’s Expansion, we have:





where L′n is a s× 1 vector and L′′n is a s× s matrix, θ1 is a vector among two balls
with radii ||θ0|| and ||θˆn||.
Then
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for θ ∈ Ω0.















Ln(θ2)(θ1 − θ0) (4.7)






















Ln(θ1) is bounded if we let ||θ1 − θ0|| less than some constant.
Therefore, in (4.3)
θˆn − θ0 P→ 0 (4.8)
Considering the consistence of θˆn, as n→∞, we have θ1 − θ0 P→ 0. Therefore,















The proof is completed.
By a weak law for martingale and standard martingale arguments, we have the
following substitute conditions:
(A5’) For j = 1, · · · , s, n−2
n∑
i=1
E{(∂/∂θj)Li(θ)}2 → 0, for all θ ∈ ω, as n→∞
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0, for all θ ∈ ω, as n→∞
(A6”) For j = 1, · · · , s, k = 1, · · · , s, n−2
n∑
i=1
V ar{(∂2/∂θj∂θk)Li(θ)} → 0, for
all θ ∈ ω, as n→∞
It should be clear that (A5’) implies (A5); (A6”) implies (A6’); and (A6’),
together with (A4), implies (A6).
Now, we will show that for a RPW rule, the MLE of success rate of each
treatment satisfies the regularity conditions and thus Theorem 1 can be applied.
Let Xi = j if the ith patient is assigned to treatment j, j = 1, · · · , s. Let Iij = 1
if Xi = j, and Iij = 0 otherwise. Let Ti = 1 if the response of the treatment is a
success, and Ti = 0 otherwise. Suppose that pj = P{Ti = 1|Xi = j}, the underlying
probability of success at treatment j. Letting Fn = σ{T1, · · · , Tn, X1, · · · , Xn}, it
was proven by Athreya and Karlin (1968) that






where vj is defined as before.
Define Y n = (Y0, · · · , Yn−1), the history of the urn composition up to and
including stage n − 1. Let T n = (T1, · · · , Tn) be the response history and Xn =
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(X1, · · · , Xn) be the treatment assignment history. Then the likelihood Ln of the
data is
Ln = {T n, Xn, Y n}
= L {Tn|T n−1, Xn, Y n}L {Xn|T n−1, Xn−1, Y n}
×L {Yn−1|T n−1, Xn−1, Y n−1}Ln−1
= L {Tn|Xn}L {Xn|yn}Ln−1
= L {Y 1}
n∏
i=1
L {Ti|Xi}L {Xi|Y i}
































The first derivative of the loglikelihood is given by









i=1 Iij, the proportion of observed
success at treatment j.
We now show that the MLE vector is asymptotically multivariate normal. Con-
ditions (A1) and (A2) are trivial to verify. For conditions (A3), we see that
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{p−2j Ei−1{TiIij}+ (1− pj)−2Ei−1{(1− Ti)Iij}}
(4.11)
It is easy to see that Ei−1{TiIij} = pjEi−1{Iij}, and hence from (4.9) and (4.10)
that γjj = vj/pj(1−pj). Since summands are bounded for each i, conditions (A5’),
(A6’) and (A6”) are trivial to verify, and therefore (A4)-(A6) are satisfied.
We conclude that the vector (for j = 1, · · · , s) with components n1/2(pˆj − pj)
is asymptotically multivariate normal with mean vector 0 and variance-covariance
matrix [Γ(p)]−1 with diagonal element pj(1− pj)/vj and off-diagonal elements 0.
When j = 2, we have the following result:
n1/2
















Let N1 and N2 denote the number of patients allocated to treatment 1 and
treatment 2 respectively. By (4.10) we have
Nj
n
a.s.−−→vj, j = 1, 2 (4.13)
Then by Slutsky’s Theorem,N
1/2
1 (pˆ1 − p1)
N
1/2










Asymptotic normality of Z statistic in (4.1) holds.
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4.3 Simulation Results
4.3.1 Choice of Design Parameters
A simulation study based on 10,000 replications was carried out to compare the two
designs described in Chapters 1 and 2. For the RPW rule, I have taken β = 1, α = 0
and studied two initial urn compositions, u = 1 and u = 3. For the group sequential
design, I set the maximum number of group K = 5, and studied two boundaries,
O’Brien-Fleming test and Pocock test. From Table 3.1 and Table 3.2 we can
find that the sequence of critical values for O’Brien-Fleming test and Pocock test
are {4.562, 3.226, 2.633, 2.281, 2.040} and {2.413, 2.413, 2.413, 2.413, 2.413} respec-
tively.
Suppose that the Type I error probability α = 0.05 and we wish to obtain power
1− β = 0.8 when |pA− pB| = 0.2. The information required by a fixed sample size
test with these error probabilities is
If = {Φ−1(0.975) + Φ−1(0.8)}2/0.22 = 196.2
Look up from Table 3.4, the inflation factor of O’Brien-Fleming test with K =
5, α = 0.05, 1 − β = 0.8 is 1.028. The maximum information level needed by the
O’Brien-Fleming test is, therefore,
Imax = IF × 196.2 = 1.028× 196.2 = 201.7
Now I will derive the maximum sample size needed from the maximum information
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level:








Solving for m, we have m =
1
5
× (pˆA5(1− pˆA5)+ pˆB5(1− pˆB5))× Imax. It is evident
that the sample size depends on the values of pˆA5 and pˆB5, which are unknown
at the design stage. However, since m varies slowly as a function of pˆA5 and pˆB5
for values away from 0 and 1, a highly accurate estimate of pˆA5 and pˆB5 is not
usually necessary. We shall continue assuming the worst case value, so any error
will be in the direction of larger size. Under alternative hypothesis, |pA−pB| = 0.2,
pˆA5(1− pˆA5)+pˆB5(1− pˆB5) achieves the maximum value when pˆA5 = 0.4, pˆB5 = 0.6
or pˆA5 = 0.6, pˆB5 = 0.4. So we have m =
1
5
×0.48×201.7 = 19.36, which we round
up to 20. Using the same method, we can have the maximum sample size for
Pocock test, which is 5 groups of 24 patients per treatment. For the RPW rule,
sample size needed is {Φ−1(0.975) + Φ−1(0.8)}2/0.22 = 196.2.
So for the purpose of comparison, we set the sample size to be 240 for all
designs. For RPW design, all 240 patients will be allocated by RPW rule. While
for group sequential designs, if we can stop early, then the remaining patients will
be allocated to the better treatment.
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pB Fixed RPW(1, 0, 1) RPW(3, 0, 1) O’Brien-Fleming Pocock
0.5 0.0486 0.0553 0.0515 0.0546 0.0609
0.55 0.1209 0.1180 0.1167 0.1353 0.1139
0.6 0.3517 0.3398 0.3533 0.3477 0.2877
0.65 0.6756 0.6492 0.6504 0.6040 0.5683
0.7 0.8980 0.8804 0.8818 0.8827 0.8232
0.75 0.9839 0.9748 0.9795 0.9809 0.9655
0.8 0.9992 0.9983 0.9972 0.9988 0.9957
0.85 1.0000 0.9998 0.9998 1.0000 1.0000
0.9 1.0000 0.9999 1.0000 1.0000 1.0000
Table 4.1: Monte Carlo estimates of power when pA = 0.5 and sample size n = 240
pB Fixed RPW(1, 0, 1) RPW(3, 0, 1) O’Brien-Fleming Pocock
0.1 0.0541 0.0545 0.0551 0.0532 0.0532
0.15 0.2251 0.2168 0.2182 0.1753 0.1792
0.2 0.5999 0.5921 0.6081 0.5807 0.5002
0.25 0.8807 0.8844 0.8826 0.8738 0.8149
0.3 0.9784 0.9789 0.9812 0.9781 0.9601
0.35 0.9979 0.9984 0.9979 0.9967 0.9941
0.4 1.0000 1.0000 1.0000 0.9998 0.9996
0.45 1.0000 1.0000 1.0000 1.0000 1.0000
0.5 1.0000 1.0000 1.0000 1.0000 1.0000
Table 4.2: Monte Carlo estimates of power when pA = 0.1 and sample size n = 240
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4.3.2 Comparison of Error Probabilities
Monte Carlo estimates of the power function for different values of pB for RPW(1,
0, 1), RPW(3, 0, 1), O’Brien-Fleming test and Pocock test are given in Table 4.1
and Table 4.2 when the sample size n = 240. For example, the entries in the
first row (pB = 0.5) of Table 4.1 give the simulated significance level and those in
the fifth row give the simulated values of the power function when pA = 0.5 and
pB = 0.7. We can see that the significance level is approximately 0.05 and the
power function achieves 0.8 when difference between two treatments is 0.2. The
power function of Pocock test is a little smaller while other designs have similar
power functions.
Monte Carlo estimates of Type I error probabilities for the four designs are
summarized in Table 4.3. We can see that when pA = pB, the attained error rate
is close to the nominal level of 0.05.
4.3.3 Comparison of Expected Treatment Failures
Table 4.4 and Table 4.5 give Monte Carlo estimates of the expected number of
treatment failure for the four designs. The result for the fixed sample test is also
provided for comparison. We can see that both RPW rule and group sequential
designs can reduce the number of treatment failures. By comparing column 2, 3, 4, 5
and 6 of Table 4.4, we see that the group sequential designs are generally more
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pA = pB RPW(1, 0, 1) RPW(3, 0, 1) O’Brien-Fleming Pocock
0.1 0.0545 0.0551 0.0532 0.0532
0.2 0.0485 0.0517 0.0529 0.0552
0.3 0.0552 0.0563 0.0542 0.0606
0.4 0.0542 0.0540 0.0555 0.0622
0.5 0.0533 0.0515 0.0546 0.0609
0.6 0.0543 0.0503 0.0554 0.0602
0.7 0.0508 0.0505 0.0541 0.0610
0.8 0.0538 0.0462 0.0541 0.0621
0.9 0.0543 0.0475 0.0482 0.0545
Table 4.3: Monte Carlo estimates of Type I error probabilities.
pB Fixed RPW(1, 0, 1) RPW(3, 0, 1) O’Brien-Fleming Pocock
0.5 120.03(7.81) 119.99(7.77) 120.04(7.71) 119.51(8.42) 117.69(12.25)
0.55 113.84(7.68) 113.69(7.72) 113.70(7.72) 112.71(9.10) 110.70(13.16)
0.6 108.15(7.62) 106.70(7.91) 106.72(7.76) 104.18(11.11) 100.86(16.54)
0.65 102.15(7.55) 98.95(8.05) 99.05(7.84) 93.15(13.30) 87.58(18.96)
0.7 96.04(7.47) 90.34(8.17) 90.78(8.06) 79.82(14.10) 72.86(18.94)
0.75 90.12(7.23) 80.84(8.42) 81.63(8.24) 66.74(12.68) 57.95(16.09)
0.8 83.92(6.97) 70.08(8.72) 71.26(8.31) 54.56(10.34) 45.49(12.07)
0.85 78.01(6.70) 57.91(8.93) 59.80(8.52) 44.03(8.39) 35.23(8.63)
0.9 71.94(6.31) 44.07(9.00) 46.89(8.40) 34.60(6.93) 26.38(6.13)
Table 4.4: Monte Carlo estimates of expected number of treatment failures (stan-
dard deviation) when pA = 0.5
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pB Fixed RPW(1, 0, 1) RPW(3, 0, 1) O’Brien-Fleming Pocock
0.1 251.96(4.66) 215.97(4.67) 216.02(4.69)) 215.13(7.28) 213.34(14.34)
0.15 209.98(5.08) 209.78(5.12) 209.84(5.19) 202.33(22.02) 202.18(22.30)
0.2 204.01(5.46) 203.30(5.65) 203.36(5.59) 190.58(20.16) 182.36(31.14)
0.25 197.96(5.79) 196.32(6.21) 196.42(6.18) 170.27(23.14) 157.88(33.25)
0.3 191.93(5.96) 188.91(6.72) 189.24(6.60) 151.44(21.45) 135.83(28.82)
0.35 185.98(6.16) 181.26(7.13) 181.27(7.16) 135.90(18.40) 119.34(23.16)
0.4 180.12(6.36) 172.85(7.71) 172.93(7.57) 122.26(15.65) 105.67(17.49)
0.45 174.06(6.29) 164.12(8.25) 164.31(8.03) 135.90(13.99) 95.23(14.13)
0.5 168.00(6.38) 154.55(8.51) 154.95(8.48) 100.54(13.25) 85.97(11.36)
Table 4.5: Monte Carlo estimates of expected number of treatment failures (stan-
dard deviation) when pA = 0.1
effective in reducing the number of treatment failures than the RPW rule. Pocock
test is more effective than O’Brien-Fleming test, but as we have mentioned before,
Pocock test has smaller power function than O’Brien-Fleming test. And RPW(1,
0, 1) is a little more effective than RPW(3, 0, 1). This is because under RPW rule,
allocation ratios become unbalanced quickly when there is difference between the
treatments and urn with less initial balls is more sensitive to the difference.
4.3.4 Results for the Combined Procedure
In the above section, we have shown that both RPW rule and group sequential
design can reduce the number of treatment failures. They accomplish this goal
using difference mechanism. So it is naturally for us to come up with the idea of
combining them together. In order to investigate the potential benefit of combining
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Table 4.6: Monte Carlo results for the combined procedure when pA = 0.5










Table 4.7: Monte Carlo estimates of the Type I error probabilities for combined
procedure when pA = 0.5
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the two designs, a further simulation study, again based on 10,000 replications, was
carried out.
Again, the number of patients n = 240 and the maximum number of interim
analyses K = 5 with 48 patients in each group. However, in each group, the pa-
tients are no longer equally allocated to each treatment, but with the RPW(1, 0, 1)
rule. And the O’Brien-Fleming boundary is used. The results for the combined
procedure are given in Table 4.6 and Table 4.7.
We can see that simulated values in column 2 of Table 4.6 and Table 4.7 are
close to the values in column 4 of Table 4.1 and Table 4.3, suggesting that the error
probabilities for the group sequential design are insensitive to the allocation rule
used. A comparison of the simulated values in column 3 with those in column 3




In this thesis I have studied two designs for comparing an experimental treatment
with a control when responses are binary and are instantly obtainable. I have shown
how to choose the design parameters for two design to achieve the error probabilities
with those for an equivalent fixed-sample design based on balanced randomization.
The main conclusion from the simulations is that the group sequential design is
generally more effective than the RPW rule at reducing the expected number of
treatment failures. It was also shown that the expected number of treatment
failures can be further reduced by combing the RPW rule and the group sequential
design.
There are, however, some interesting issues raised by the results and also several
possible extensions to the present work. In Section 4.3.3, when I compare the RPW
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rule and the group sequential design, the total number of patients was the same for
the two designs. This approach was taken in order to make the comparison fair. Of
course, the advantage of group sequential design would generally be much greater
if one only compare the expected numbers of treatment failures within the trial,
since the group sequential design will tend to stop early, especially if the difference
between pA and pB is quite large.
It would also be valuable to investigate whether the expected number of treat-
ment failures can be further reduced by using alternative adaptive design, such as
those studied by Bather (1985).
One obvious extension to the present work is to develop a model with delayed
patient response. Such developments could be attractive from a practical point of







sum<-0 #number of failures of current loop
p<-0.5 #success rate of treatment A
q<-0.5 #success rate of treatment B
fail<-c(rep(0,10000)) #number of failures
for(Repeat in 1:10000) {
time<-0
r<-1 #initial urn composition
nA<-0 #patients allocated to treatment A
nB<-0 #patients allocated to treatment B
sA<-0 #number of success of treatment A





















if(nA==0) pA<-0 else pA<-sA/nA


















































































































































if(nA==0) pA<-0 else pA<-sA/nA
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